ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rituximab

Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.

Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.

Drug pageRituximab: every studyMany companies study it; this page follows only the 124 they lead. All 1,284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 18, 2007124 company-led studies, 6 open or runningNext primary completion: Oct 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche781 open or runningphase 4since Jan 18, 2007Apr 1, 2003none ahead
SymBio Pharmaceuticalsits history only50 open or runningphase 3since Dec 10, 2017Nov 18, 2008none ahead
AbbVieits history only40 open or runningphase 3since Jun 9, 2014Apr 20, 2012none ahead
AstraZenecaits history only42 open or runningphase 4since Aug 23, 2023Apr 8, 2016Oct 31, 2028phase 2 · NCT05951959
Biogenits history only40 open or runningphase 4since Aug 23, 2004Mar 31, 2003none ahead
Takedaits history only40 open or runningphase 3since Apr 7, 2006Jun 11, 2004none ahead
Biocadits history only30 open or runningphase 3since Oct 3, 2012Oct 3, 2012none ahead
Celltrionits history only30 open or runningphase 1since Feb 8, 2012Feb 8, 2012none ahead
Favrilleits history only30 open or runningphase 3since Aug 4, 2004Aug 4, 2004none ahead
GlaxoSmithKlineits history only20 open or runningphase 3since Oct 13, 2017Dec 14, 2015none ahead

Also a collaborator on its studies: ICON Clinical Research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, Roche Pharma and Chiron.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Jan 31, 2007.

  1. Mar 4, 20142 phase 3 studies in Arthritis, RheumatoidNCT02079532, NCT02097745
  2. Mar 19, 2014Phase 2 study in Arthritis, RheumatoidNCT02093026 · 465 enrolled · United States, Australia, Belgium and more
  3. Apr 14, 2014Phase 4 study in Granulomatosis with PolyangiitisNCT02115997 · 30 enrolled · India
  4. Oct 2, 2014Phase 2 study in LymphomaNCT02257567 · 331 enrolled · United States, Australia, Canada and more
  5. Mar 4, 20152 phase 3 studiesNCT02383589, NCT02406092
  6. Aug 24, 2015Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02533401 · 34 enrolled · Argentina, Venezuela
  7. Sep 23, 2015Phase 3 study in Lymphoma, FollicularNCT02569996 · 124 enrolled · Hungary
  8. Nov 3, 2015Phase 2 study in RecurrenceNCT02600897 · 114 enrolled · United States, Spain, United Kingdom
  9. Feb 23, 2016Phase 2 study in Arthritis, RheumatoidNCT02693210 · 161 enrolled · Australia, Belgium, Canada and more
  10. Jul 22, 2019Phase 1 study in Multiple MyelomaNCT04045028 · 41 enrolled · United States, Korea, Republic of
  11. Nov 25, 2020Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04660799 · 50 enrolled · China
  12. Jan 13, 2021Phase 3 study in RecurrenceNCT04712097 · 478 enrolled · United States, Australia, Brazil and more
  13. Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04790903 · 50 enrolled · United States, France, Italy and more
  14. May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT05364424 · 43 enrolled · United States
  15. Jan 29, 2026Named rituximabINNProposed as its International Nonproprietary Name in WHO's List 134 · before, MK-8808

TargetBeta

MS4A1 →read by rule
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

The newest 60 of 78 Hoffmann-La Roche leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT05364424Lymphoma, Large B-Cell, Diffuse · United States1CompletedOct 15, 202543
NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more1TerminatedMay 21, 202450
NCT04712097Recurrence · United States, Australia, Brazil and more3Active, not recruitingJun 3, 2026478
NCT04660799Lymphoma, Large B-Cell, Diffuse · China2CompletedMay 23, 202250
NCT04045028Multiple Myeloma · United States, Korea, Republic of1TerminatedMar 28, 202341
NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more2CompletedAug 2002161
NCT02600897Recurrence · United States, Spain, United Kingdom2CompletedDec 15, 2021114
NCT02569996Lymphoma, Follicular · Hungary3CompletedAug 2013124
NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela2CompletedDec 201434
NCT02406092Lymphoma, Non-Hodgkin · Algeria, Morocco, Tunisia3CompletedJun 30, 2021139
NCT02383589Pemphigus · United States, Argentina, Australia and more3CompletedNov 28, 2018135
NCT02257567Lymphoma · United States, Australia, Canada and more2CompletedOct 21, 2021331
NCT02115997Granulomatosis with Polyangiitis · India4CompletedJun 7, 202230
NCT02097745Arthritis, Rheumatoid · United States, Belgium, Canada and more3CompletedJun 2013341
NCT02093026Arthritis, Rheumatoid · United States, Australia, Belgium and more2CompletedDec 2012465
NCT02079532Arthritis, Rheumatoid · Germany3CompletedNov 2010302
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedJun 28, 2017267
NCT02006706Arthritis, Rheumatoid · Serbia3CompletedNov 23, 200715
NCT02013817Leukemia, Lymphocytic, Chronic, B-Cell · Austria2CompletedSep 24, 201243
NCT01998893Lymphoma, Non-Hodgkin · Germany2CompletedFeb 200838
NCT01987505Lymphoma, Non-Hodgkin · Spain3CompletedApr 11, 2017140
NCT01889069Lymphoma · Italy3CompletedMay 28, 2019159
NCT01750697Granulomatosis with Polyangiitis · United States, Canada, France and more2CompletedMay 10, 201825
NCT01724021Lymphoma, Large B-Cell, Diffuse · Argentina, Australia, Austria and more3CompletedJan 2015743
NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany1CompletedAug 17, 201884
NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more3CompletedOct 21, 2014572
NCT01461928Lymphoma, Non-Hodgkin · Albania, Argentina, Austria and more3CompletedJun 2, 2018692
NCT01392716Lymphoma, Non-Hodgkin · France2CompletedFeb 200648
NCT01388959Lymphoma, Non-Hodgkin · France2CompletedApr 200440
NCT01382940Arthritis, Rheumatoid · United States4CompletedJan 6, 2013351
NCT01272908Arthritis, Rheumatoid · Canada, Sweden3CompletedMar 12, 2009120
NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation4TerminatedMay 4, 201689
NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel2CompletedApr 3, 201742
NCT01200758Lymphoma, Non-Hodgkin · Australia, Belgium, Bosnia and Herzegovina and more3CompletedJun 12, 2012410
NCT01153971Lymphoma, Non-Hodgkin · Italy2CompletedSep 24, 201047
NCT01144403Lymphoma, Large B-Cell, Diffuse · Romania2TerminatedAug 20148
NCT01144364Lymphoma, Non-Hodgkin · Italy3CompletedJul 21, 2011234
NCT01126541Arthritis, Rheumatoid · France3CompletedNov 2011224
NCT01117129Arthritis, Rheumatoid · Spain4TerminatedJun 20102
NCT01087151Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more2CompletedJun 2012118
NCT00930514Lymphoma, Follicular · Argentina, Australia, Brazil and more1CompletedJul 2013281
NCT00845832Arthritis, Rheumatoid · France, Germany, Greece and more2TerminatedMar 201324
NCT00770562Purpura, Thrombocytopenic, Idiopathic · Italy3CompletedJul 2008103
NCT00719472Lymphoma, Non-Hodgkin3CompletedMay 2011451
NCT00718549Leukemia, Lymphocytic, Chronic, B-Cell · Belarus, Poland3CompletedSep 14, 2015128
NCT00578305Arthritis, Rheumatoid · Argentina, Brazil, Canada and more3CompletedNov 2009185
NCT00576433Arthritis, Rheumatoid · Russian Federation4CompletedNov 201060
NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain2CompletedMay 20, 201686
NCT00532129Leukemia, Lymphocytic, Chronic, B-Cell · United Kingdom2CompletedApr 2012100
NCT00517699Lymphoma · Canada2TerminatedMar 20095
NCT00503425Arthritis, Rheumatoid · Israel3CompletedMay 26, 2013215
NCT00502996Arthritis, Rheumatoid · Argentina, Brazil, Chile and more3CompletedDec 2008246
NCT00502853Arthritis, Rheumatoid · Italy4CompletedJul 23, 201010
NCT00502840Arthritis, Rheumatoid · Germany3CompletedSep 20, 2011193
NCT00475423Purpura, Thrombocytopenic, Idiopathic · Australia2CompletedAug 2011122
NCT00472420Lymphoma, Mantle-Cell · Hungary2CompletedMay 25, 201148
NCT00468546Arthritis, Rheumatoid · United States, Belgium, Canada and more3CompletedJan 2005520
NCT00462345Arthritis, Rheumatoid · Korea, Republic of4CompletedJul 200940
NCT00443651Arthritis, Rheumatoid3CompletedMay 2011578
NCT00430352Lymphoma, Non-Hodgkin · Albania, Argentina, Australia and more4CompletedMay 26, 2011545

How it is read

Names in the registry

  • “Rituximab”, 104 entries
  • “rituximab”, 34 entries
  • “rituximab [MabThera/Rituxan]”, 23 entries
  • “Rituximab SC”, 2 entries
  • “MK-8808”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.